Patent foramen ovale closure in India; Feasibility, challenges and mid-term outcomes

Viji S. Thomson a, *, Sanjith Aaron b, Nathaniel Samson D a, Jesu Krupa a, A.T. Prabhakar b, John Jose a, Paul George a, Oommen K. George a, George Joseph a, Bijesh Kumar Yadav c

a Department of Cardiology, Christian Medical College and Hospital, Vellore, 632004, India
b Department of Neurology, Christian Medical College and Hospital, Vellore, 632004, India
c Department of Biostatistics, Christian Medical College and Hospital, Vellore, 632004, India

Abstract

Patent foramen ovale closure (PFO) is an underutilized therapy, and our study explored the challenges and feasibility of PFO closure in the Indian setting.

Eighty patients with Embolic Stroke of Undetermined Source (ESUS) were screened by transcranial Doppler (TCD) for PFO. Twenty-nine patients underwent successful closure. High-risk features of a long tunnel, inter-atrial septal aneurysm, and large defect were present in 31%, 28%, and 59%. Transcranial Doppler had a sensitivity and specificity of 78% and 53% (p = 0.02) to detect PFO. Anticoagulation was withdrawn in 85% of patients post closure. Two patients had residual shunts at follow-up of 19 (9,34) months.

© 2021 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Three randomized trials proved the superiority of percutaneous PFO closure over medical therapy with antiplatelet agents in cryptogenic stroke when PFO was associated with high-risk attributes for stroke.1-4 Data from anticoagulation trials using Vitamin K antagonists in the Asian population suggest increased adverse events than the Caucasian population.5 Thus, PFO closure may prove to be a superior strategy for preventing recurrent stroke in young Indian patients.

2. Methodology

The institutional review board cleared the study (Mi. No.13438). Neurologists evaluated patients presenting with ischemic stroke for aetiology of stroke. If all other workups for ischemic stroke (Supplementary data 2.0) were negative, a TCD evaluation was performed in the stroke clinic to screen for PFO. If it was positive, and or the patient had a high risk of paradoxical embolism (RoPE) score,5 they were referred for a transoesophageal echocardiogram (TEE) study to exclude PFO.

2.1. TEE protocol

The presence of PFO was confirmed by Transoesophageal echo (TEE) Agitated Saline Contrast (ASC) study (Fig. 1). The shunt was quantified using the Soliman et al grading.7 The detailed TEE examination protocol, the high-risk attributes of the PFO (supplementary data 2.1), and the proforma used for capturing data is given in Appendix B.

The 25 mm Amplatzer PFO occluder (St. Jude Medical, Zaventem, Belgium) device was used in 83% of cases. All procedures were performed under conscious sedation from the right femoral venous approach using the 9 French Amplatzer Torque Vue delivery system and TEE guidance. The details of device selection, sedation, and adjunct medications are given in Supplementary data (Sections 2.2,2.3,2.4). Post closure, all the patients received dual antiplatelet therapy for six months, followed by a single antiplatelet agent.

2.2. Statistical analysis

Categorical variables were expressed as n (%) and continuous variables as mean ± standard deviation (SD) or median with interquartile ranges (IQR) depending on the variable's distribution.
The Chi-square test or Fisher’s exact test was used to ascertain the association between categorical variables. A p-value of $<0.05$ was taken to be statistically significant.

3. Results

Sixty-six of 88 patients referred for PFO evaluation had a PFO on TEE and were counselled to undergo closure. Thirty-one came forward, and twenty-nine underwent PFO closure between June 2014 to February 2020.

The baseline features of patients and high risk attributes of PFO are given in Table 1.

3.1. Correlation between TCD grade and PFO size and shunting

In our study ≥30 High-intensity transient signals (HITS), on TCD had a sensitivity and specificity of 78% and 53% ($p = 0.02$),
respectively. The positive and negative predictive values were 82 and 45%, respectively. The mean size of the defect (5.1 ± 4.2) mm observed in a large shunt was significantly larger than a small (1.8 ± 0.8) or moderate shunt (1.9 ± 0.9) (p < 0.05). No correlation was observed between the TCD or the TEE shunt size when the PFO defect was stratified as small < 2 mm or large ≥ 2 mm.2

3.2. Antiplatelet and anticoagulant drugs

In 85% of the patients, anticoagulation was discontinued. Eighteen per cent were free of anticoagulant or antiplatelet medications, and 54% were on a single antiplatelet agent at follow-up.

3.3. Technical success

Successful closure was achieved in 94% of patients. In two patients, PFO could not be crossed due to unfavourable anatomy. Two patients had small residual shunts at the nine-month follow-up. There were no recurrent strokes or TIA in those who underwent closure at a median follow-up of 19 (9, 34) months.

3.4. Adverse events

One patient developed air embolism, which recovered without any sequelae. The second patient developed intraprocedural atrial fibrillation (AF) and was treated with direct current cardioversion. There were no periprocedural strokes, access site complications, or bleeding complications.

4. Discussion

In India, cerebrovascular disease is second only to ischemic heart disease for non-communicable disease-related mortality and in 28% of the patients with ischemic stroke, the aetiology was unknown.13 The prevalence of PFO in Indian stroke patients is not known.

TCD as a screening test for PFO in our study had fair sensitivity but had low specificity and negative predictive value. Hence in patients with strong clinical suspicion of PFO with a high RoPE score, a TEE ASC study is warranted.

Meta-analysis and systematic reviews have confirmed the superiority of PFO closure compared to medical therapy but carry a small significant risk of new-onset AF.1–3,8,11–13

In our case series, one patient developed periprocedural AF, which was successfully cardioverted.

Two (6.8%) of our patients had small residual shunts confirmed on TEE at nine months. One patient had a hypermobile septum with a long PFO tunnel of 15 mm, and the second patient had multiple fenestrations in the interatrial septum. In both these cases, the degree of shunting was less by two grades on TCD from baseline. Residual shunts have been identified in 22–26% of patients who undergo PFO closure.14,15 Deng et al documented an increased incidence of recurrent events with moderate to large residual shunts, but the significance of small shunts remains unknown.14

Anticoagulation could be withdrawn in 85% of the patients. Two patients were continued on anticoagulation because of small residual shunts, and another had chronic AF requiring anticoagulation. In the latter patient, the cardio-neuro team decided on PFO closure because of recurrent stroke despite anticoagulation.

PFO closure for ESUS is an attractive option for Indian patients due to the scarcity of reliable laboratories to monitor anticoagulation therapy, prohibitive costs of novel anticoagulant agents (NOAC’s), and poor compliance with treatment.

The impediment to the widespread application of this therapy include:

1. Lack of awareness among physicians regarding PFO related strokes.
2. Lack of multidisciplinary (cardiology-neurology) team to diagnose and treat PFO related ESUS.
3. Cost of the device.

In our institute, the formation of a heart-stroke team helped to overcome some of these challenges. The neurologists should be the gatekeepers of this therapy in choosing the appropriate patient for PFO closure since incidental PFO’s occur in 25% of the population.

A concerted effort from all cardiology and neurology forums and societal bodies is required to maximize the benefit of PFO closure for young Indian patients with ESUS.

Key message

PFO closure is beneficial in patients who have high risk anatomical attributes for ESUS; establishing a cardio-neurology team is crucial in identifying and triaging patients to maximize the benefit of this therapy in the Indian setting.
Declaration of competing interest

None of the authors have any conflicts of interest and there was no sponsorship or funding received for the preparation of this manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ihj.2021.09.001.

References

1. Mas JL, Derumeaux G, Guillou B, et al. Patent foramen ovale closure or anti-coagulation vs antiplatelets after stroke. N Engl J Med. 2017;377:1011–1021.
2. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022–1032.
3. Sondergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377:1033–1042.
4. Mojadidi MK, Elgendy AY, Elgendy IY, et al. Transcatheter patent foramen ovale closure after cryptogenic stroke: an updated meta-analysis of randomized trials. JACC Cardiovasc Interv. 2017;10:2228–2230.
5. Chang C-E, Wang K-L, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemostasis. 2014;112:789–797.
6. Kent DM, Ruthazer R, Weimar C, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013;81:619–625.
7. Soliman OI, Geleijnse ML, Meijboom FJ, et al. The use of contrast echocardiography for the detection of cardiac shunts. Eur J Echocardiogr. 2007;8:s2–s12.
8. Lao AV, Sharma VK, Tsvygoulis G, et al. Detection of right-to-left shunts: comparison between the international consensus and spencer logarithmic scale criteria. J Neuroimaging. 2008;18:402–406.
9. Nakayama R, Takaya Y, Akagi T, et al. Identification of high-risk patent foramen ovale associated with cryptogenic stroke: development of a scoring system. J Am Soc Echocardiogr. 2019;32:811–816. https://doi.org/10.1016/j.echo.2019.03.021. In this issue.
10. Sylaja PN, Pandian JD, Kaul S, et al. Ischemic stroke profile, risk factors, and outcomes in India: the indo-US collaborative stroke project. Stroke. 2018:49:219–222.
11. Wang TKM, Wang MMT, Ruygrok P. Patent foramen ovale closure versus medical therapy for cryptogenic stroke: meta-analysis of randomised trials. Heart Lung Circ. 2019;28:623–631.
12. Nasir UB, Qureshi WT, Jogi H, et al. Updated meta-analysis of closure of patent foramen ovale versus medical therapy after cryptogenic stroke. Cardiovasc Revascularization Med. 2019;20:187–193.
13. Vaduganathan M, Qamar A, Gupta A, et al. Patent foramen ovale closure for secondary prevention of cryptogenic stroke: updated meta-analysis of randomized clinical trials. Am J Med. 2018;131:575–577.
14. Deng W, Yin S, McMullin D, et al. Residual shunt after patent foramen ovale closure and long-term stroke recurrence: a prospective cohort study. Ann Intern Med. 2020;172:717–725.
15. Moon J, Kim M, Oh PC, et al. Residual shunt after patent foramen ovale device closure in patients with cryptogenic stroke: serial bubble contrast transesophageal echocardiography data. J Stroke Cerebrovasc Dis. 2019;28:347–353.